Orthocell Limited (ASX:OCC) is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI*TM) and Autologous Chondrocyte Implantation (Ortho-ACI*TM), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro*TM, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.
Orthocell Limited
ASX:OCC ISIN:AU000000OCC6
News
The Directors of Chapmans Limited (ASX:CHP) are pleased to announce that the Company has entered into a Binding Heads of Agreement with MJ Life Sciences Pty Ltd, to make a strategic investment of US$500,000 in MJLS.
Regenerative medicine company Orthocell Limited (ASX:OCC) announced today its success in growing human tendons in a laboratory for the first time.
###
9,793 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 12) (Last 30 Days: 35) (Since Published: 5285)